BYSI (BeyondSpring Pharma) חוב לטווח ארוך

BeyondSpring Inc. (BYSI) is implementing predictive software and laboratory automation to accelerate the discovery of molecules targeting lung cancer. The business model relies on creating a supportive therapy environment where Plinabulin protects leukocytes during chemotherapy. The metric stands at 0.00. This chart of the company's market valuation reflects price action amid volatility, dependence on Chinese clinics, and the risks of drug rejection by the FDA.

High debt leverage increases the vulnerability of BeyondSpring Inc. (BYSI) to regulatory risks and delays in the approval of oncology drugs. Analyzing the value of the firm's long-term borrowings, an investor assesses management's ability to fund clinical trials without compromising solvency, where a stable trend confirms control over liabilities, while stagnation signals a capital deficit for scaling the business.